Wednesday, July 08, 2026 CCTG LY18 Cohort A primary publication: A phase 1 study of R-GDP–venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18) Although chimeric antigen receptor T-cell therapy has supplanted autologous stem cell transplantation (ASCT) for most patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma after 1 line of therapy, ASCT may still be a suitable therapy for some patients, especially those with late relapse. Rituximab, gemcitabine, dexamethasone and cisplatin (R-GDP) is an established salvage chemotherapy regimen used to induce responses before ASCT. LY.18 is a phase I platform study aimed at adding new agents to R-GDP to determine their safety and recommended phase 2 dose. The first arm of LY.18 tested escalating dose levels of venetoclax in combination with 3 cycles of R-GDP at standard doses. In total, 24 patients were treated. Assouline S, Prica A, Villa D, Kridel R, Johnson N, Kukreti V, Shamy A, Kaedbey R, Gerrie A, Savage K, Kelly J, Shepherd LE, Hay AE, Scott DW, Crump M, Chen BE, Kuruvilla J. A phase 1 study of R-GDP–venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18). Blood Neoplasia 3: 100233. 2026.https://www.sciencedirect.com/science/article/pii/S2950328026000440
